NANOCELLE® B12

Background

Work into NanoCelle® B12 was a key study program. Essentially NanoCelle® was designed to improve solubility for utilisation with insoluble compounds.

B12 is a water-soluble compound, thus this foundation study was to determine NanoCelle® improvement in water-soluble compounds when compared to other more traditional forms, such as tablets, liquid emulsions, capsules, and liposomes.

The Study - Ethics approved and published

16 healthy people were randomised across 5 arms, crossed over. The study duration was 6 months. All participants were on a diet to limit B12 consumption. participants were blinded and given either NanoCelle® B12 or a commercial B12 supplement purchased through an Australian pharmacy, these included: tablets, capsules, liquid emulsion, or a liposome. All dosages were 1,000IU. Blood work was collected at baseline, and then at intervals up too 6 hours post.

The Results

From 314 serum collections, NanoCelle® B12 arm showed superiority over all trialed arms (by a factor of up too 5x absorption) with liposomal B12 performing the worst. The published study can be found here.

As a direct result of the study, the TGA approved a specific claim for Medlab NanoCelle® B12 (for the former owner and marketer, Medlab Clinical Limited) as per below.

Historical, approved television advertisement from Medlab Clinical.